Iktos
Iktos47About
Iktos pioneers AI and robotics for drug discovery, offering an integrated platform that transforms the development of new treatments. Their core offerings include Makya, a generative AI platform for molecular design, and Spaya, an AI-driven retrosynthesis tool, both designed to accelerate the DMTA cycle. Iktos serves chemists and researchers by providing solutions for innovative molecular design, efficient synthesis planning, and fully automated laboratory processes.
Frequently asked
What does Iktos do?
Iktos pioneers AI and robotics for drug discovery, offering an integrated platform that transforms the development of new treatments. Their core offerings include Makya, a generative AI platform for molecular design, and Spaya, an AI-driven retrosynthesis tool, both designed to accelerate the DMTA cycle. Iktos serves chemists and researchers by providing solutions for innovative molecular design, efficient synthesis planning, and fully automated laboratory processes.
Where is Iktos headquartered?
Iktos is headquartered in Paris, France.
When was Iktos founded?
Iktos was founded in 2017.
What industry does Iktos operate in?
Iktos operates in AI Drug Discovery, Biotech, HealthTech, Drug Discovery, Generative AI, Foundation Model.
Comments
No comments yet. Be the first to share your take.